Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Invested Capital (2020 - 2025)

Historic Invested Capital for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$89.7 million.

  • Foghorn Therapeutics' Invested Capital fell 21695.83% to -$89.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.7 million, marking a year-over-year decrease of 21695.83%. This contributed to the annual value of -$45.5 million for FY2024, which is 4101.83% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Invested Capital stood at -$89.7 million for Q3 2025, which was down 21695.83% from -$76.7 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Invested Capital registered a high of $144.9 million during Q1 2021, and its lowest value of -$97.5 million during Q1 2024.
  • For the 5-year period, Foghorn Therapeutics' Invested Capital averaged around -$576421.1, with its median value being -$24.6 million (2023).
  • Per our database at Business Quant, Foghorn Therapeutics' Invested Capital surged by 24317.91% in 2021 and then crashed by 6901964.29% in 2023.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Invested Capital stood at $96.9 million in 2021, then tumbled by 99.88% to $112000.0 in 2022, then crashed by 69019.64% to -$77.2 million in 2023, then surged by 41.02% to -$45.5 million in 2024, then plummeted by 96.93% to -$89.7 million in 2025.
  • Its Invested Capital stands at -$89.7 million for Q3 2025, versus -$76.7 million for Q2 2025 and -$61.7 million for Q1 2025.